LOTTE Fine Chemical롯데정밀화학

LOTTE Fine Chemical's trailing earnings have recovered from 2024 lows, but the shares have fallen about 9% over the past year.

Trailing twelve-month revenue to H1 2026 was ₩1.98T with operating income of ₩141B and net income of ₩201B, against a ₩1.07T market value at ₩41,500 a share. The balance sheet looks light, with liabilities at 11.1% of equity, cash of ₩297B and borrowings of only ₩0.9B. The data does not include analyst ratings, price targets or consensus forecasts.

What stands out

• Operating margin was 7.1% on a trailing basis, up from 3.0% in 2024 but well below the 16.4% of 2022.
• Net income of ₩201B exceeds operating income of ₩141B on a trailing basis, so non-operating items or other income appear to have contributed; the data does not break this down.
• The shares trade near their 52-week low of ₩40,050 versus a high of ₩71,800, with returns of -10.1% over one month and -8.8% over one year.
• The model's DCF base value is ₩24,939 per share, below the current price, while the bull case is ₩52,156; these are model outputs, not forecasts.
• Recent filings include preliminary consolidated earnings on 30 July 2026 and the half-year report on 14 August 2026, but no recent news headlines were provided.

What to watch

• The full-year 2026 results and the next quarterly report, which will show whether margins hold up against the trailing figures.
• The amended annual report for December 2025 filed on 14 August 2026, in case it changes the reported numbers.
• Foreign ownership, investor flow and short-balance data are missing from the pack, so institutional positioning cannot be assessed.